These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 34055603)

  • 1. Differential Predictors and Clinical Implications Associated With Long-Term Survivors in IDH Wildtype and Mutant Glioblastoma.
    Jiang H; Yu K; Cui Y; Ren X; Li M; Zhang G; Yang C; Zhao X; Zhu Q; Lin S
    Front Oncol; 2021; 11():632663. PubMed ID: 34055603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term survival in patients with IDH-wildtype glioblastoma: clinical and molecular characteristics.
    Chehade G; Lawson TM; Lelotte J; Daoud L; Di Perri D; Whenham N; Duprez T; Tajeddine N; Tissir F; Raftopoulos C
    Acta Neurochir (Wien); 2023 Apr; 165(4):1075-1085. PubMed ID: 36920664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular profiling of long-term IDH-wildtype glioblastoma survivors.
    Burgenske DM; Yang J; Decker PA; Kollmeyer TM; Kosel ML; Mladek AC; Caron AA; Vaubel RA; Gupta SK; Kitange GJ; Sicotte H; Youland RS; Remonde D; Voss JS; Fritcher EGB; Kolsky KL; Ida CM; Meyer FB; Lachance DH; Parney IJ; Kipp BR; Giannini C; Sulman EP; Jenkins RB; Eckel-Passow JE; Sarkaria JN
    Neuro Oncol; 2019 Nov; 21(11):1458-1469. PubMed ID: 31346613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in methylation profiles between long-term survivors and short-term survivors of IDH-wild-type glioblastoma.
    van der Meulen M; Ramos RC; Voisin MR; Patil V; Wei Q; Singh O; Climans SA; Kalidindi N; Or R; Aldape K; Diamandis P; Munoz DG; Zadeh G; Mason WP
    Neurooncol Adv; 2024; 6(1):vdae001. PubMed ID: 38312227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular features of glioblastomas in long-term survivors compared to short-term survivors-a matched-pair analysis.
    Sommerlath VN; Buergy D; Etminan N; Brehmer S; Reuss D; Sarria GR; Guiot MC; Hänggi D; Wenz F; Petrecca K; Giordano FA
    Radiat Oncol; 2022 Jan; 17(1):15. PubMed ID: 35073955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive molecular characterization of long-term glioblastoma survivors.
    Xu H; Chen X; Sun Y; Hu X; Zhang X; Wang Y; Tang Q; Zhu Q; Song K; Chen H; Sheng X; Yao Y; Zhuang D; Chen L; Mao Y; Qin Z
    Cancer Lett; 2024 Jul; 593():216938. PubMed ID: 38734160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term survivors of glioblastoma: Tumor molecular, clinical, and imaging findings.
    Briceno N; Vera E; Komlodi-Pasztor E; Abdullaev Z; Choi A; Grajkowska E; Kunst T; Levine J; Lindsley M; Fernandez K; Reyes J; Boris L; Burton E; Panzer M; Polskin L; Penas-Prado M; Pillai T; Theeler BJ; Wu J; Wall K; Papanicolau-Sengos A; Quezado M; Smirniotopoulos J; Aldape K; Armstrong TS; Gilbert MR
    Neurooncol Adv; 2024; 6(1):vdae019. PubMed ID: 38420614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term survivors in 976 supratentorial glioblastoma, IDH-wildtype patients.
    Aboubakr O; Moiraghi A; Elia A; Tauziede-Espariat A; Roux A; Leclerc A; Planet M; Bedioui A; Simboli GA; Dhermain F; Parraga E; Benevello C; Fathallah H; Muto J; Chrétien F; Dezamis E; Oppenheim C; Varlet P; Zanello M; Pallud J
    J Neurosurg; 2024 Aug; ():1-13. PubMed ID: 39213667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive value of MGMT promoter methylation on the survival of TMZ treated
    Chai R; Li G; Liu Y; Zhang K; Zhao Z; Wu F; Chang Y; Pang B; Li J; Li Y; Jiang T; Wang Y
    Cancer Biol Med; 2021 Feb; 18(1):272-282. PubMed ID: 33628600
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Mittlmeier LM; Suchorska B; Ruf V; Holzgreve A; Brendel M; Herms J; Bartenstein P; Tonn JC; Unterrainer M; Albert NL
    Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34202726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An independently validated nomogram for isocitrate dehydrogenase-wild-type glioblastoma patient survival.
    Gittleman H; Cioffi G; Chunduru P; Molinaro AM; Berger MS; Sloan AE; Barnholtz-Sloan JS
    Neurooncol Adv; 2019; 1(1):vdz007. PubMed ID: 31608326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of Factors Associated with Long-Term Survival in Patients with Glioblastoma.
    Madhugiri VS; Moiyadi AV; Shetty P; Gupta T; Epari S; Jalali R; Subeikshanan V; Dutt A; Sasidharan GM; Roopesh Kumar VR; Shankar Ganesh CV; Ramesh AS; Sathia Prabhu A
    World Neurosurg; 2021 May; 149():e758-e765. PubMed ID: 33540096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. O
    Alassiri AH; Alkhaibary A; Al-Sarheed S; Alsufani F; Alharbi M; Alkhani A; Aloraidi A
    Ann Saudi Med; 2019; 39(6):410-416. PubMed ID: 31804140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic importance of temozolomide-induced neutropenia in glioblastoma, IDH-wildtype patients.
    Saito T; Sugiyama K; Hama S; Yamasaki F; Takayasu T; Nosaka R; Muragaki Y; Kawamata T; Kurisu K
    Neurosurg Rev; 2018 Apr; 41(2):621-628. PubMed ID: 28887717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term survival after glioblastoma resection: hope despite poor prognosis factors.
    Costa E; Lawson TM; Lelotte J; Fomekong E; Vaz RG; Renard L; Whenham N; Raftopoulos C
    J Neurosurg Sci; 2019 Jun; 63(3):251-257. PubMed ID: 29363298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
    Li H; Li J; Cheng G; Zhang J; Li X
    Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arterial spin labeling perfusion-weighted imaging aids in prediction of molecular biomarkers and survival in glioblastomas.
    Yoo RE; Yun TJ; Hwang I; Hong EK; Kang KM; Choi SH; Park CK; Won JK; Kim JH; Sohn CH
    Eur Radiol; 2020 Feb; 30(2):1202-1211. PubMed ID: 31468161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation and isocitrate dehydrogenase-1 (IDH-1) mutation in glioblastoma multiforme patients: A single-center experience in the Middle East region.
    Ayoub Z; Geara F; Najjar M; Comair Y; Khoueiry-Zgheib N; Khoueiry P; Mahfouz R; Boulos FI; Kamar FG; Andraos T; Saadeh F; Kreidieh F; Abboud M; Skaf G; Assi HI
    Clin Neurol Neurosurg; 2019 Jul; 182():92-97. PubMed ID: 31108342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topographical Mapping of 436 Newly Diagnosed IDH Wildtype Glioblastoma With vs. Without MGMT Promoter Methylation.
    Incekara F; van der Voort SR; Dubbink HJ; Atmodimedjo PN; Nandoe Tewarie R; Lycklama G; Vincent AJPE; Kros JM; Klein S; van den Bent M; Smits M
    Front Oncol; 2020; 10():596. PubMed ID: 32477929
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparative analysis of deeply phenotyped GBM cohorts of 'short-term' and 'long-term' survivors.
    Biswas A; Salvucci M; Connor K; Düssmann H; Carberry S; Fichtner M; King E; Murphy B; O'Farrell AC; Cryan J; Beausang A; Heffernan J; Cremona M; Hennessy BT; Clerkin J; Sweeney KJ; MacNally S; Brett F; O'Halloran P; Bacon O; Furney S; Verreault M; Quissac E; Bielle F; Ahmed MH; Idbaih A; Leenstra S; Ntafoulis I; Fabro F; Lamfers M; Golebiewska A; Hertel F; Niclou SP; Yen RTC; Kremer A; Dilcan G; Lodi F; Arijs I; Lambrechts D; Purushothama MK; Kel A; Byrne AT; Prehn JHM
    J Neurooncol; 2023 Jun; 163(2):327-338. PubMed ID: 37237151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.